Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature

Rohit Gulati  
*Henry Ford Health System*

Yaser Alkhatib  
*Henry Ford Health System, yalkhat1@hfhs.org*

Vijayalakshmi Donthireddy  
*Henry Ford Health System, vdonth1@hfhs.org*

Michelle Madden Felicella  
*Henry Ford Health System*

Madhu P. Menon  
*Henry Ford Health System, mmenon2@hfhs.org*

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/pathology_articles](https://scholarlycommons.henryford.com/pathology_articles)

**Recommended Citation**

Gulati R, Alkhatib Y, Donthireddy V, Felicella MM, Menon MP, and Inamdar KV. Isolated ocular manifestation of relapsed chronic myelogenous leukemia presenting as myeloid blast crisis in a patient on imatinib therapy: A case report and review of the literature. Case Rep Pathol 2015; 2015:380451.

This Article is brought to you for free and open access by the Pathology and Laboratory Medicine at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Pathology Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
Case Report

Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature

Rohit Gulati, Yaser Alkhatib, Vijayalakshmi Donthireddy, Michelle Madden Felicella, Madhu P. Menon, and Kedar V. Inamdar

Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA

Correspondence should be addressed to Kedar V. Inamdar; kinamda1@hfhs.org

Received 29 September 2015; Revised 10 November 2015; Accepted 30 November 2015

Copyright © 2015 Rohit Gulati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Blast phase in chronic myelogenous leukemia (CML) has rarely been reported to involve extramedullary sites like skin, lymph nodes, and central nervous system. Clinical history, characteristic hematologic findings (elevated leukocyte counts, myelocytic predominance, and basophilia), and Philadelphia chromosome are of high diagnostic significance especially in isolated extramedullary presentations. We describe a unique case of CML relapse with blast phase involving the eye. A 66-year-old man with a known diagnosis of CML on imatinib and in molecular remission for 3 years presented with a painful blind eye. Histologic examination revealed diffuse involvement of choroid, iris, vitreous humor, and the optic nerve by blast cells. The blasts expressed CD34, aberrant TdT, and a myeloid phenotype (CD13, CD33, and CD117). Fluorescence in situ hybridization (FISH) of vitreous fluid detected \( BCR-ABL1 \) gene rearrangement. Additionally, trisomy 8 and gains of 9 and 22 were seen which were not present in the initial diagnostic marrow study 3 years ago. At relapse, the bone marrow, peripheral blood, and the cerebrospinal fluid were not involved by CML. Patient received induction chemotherapy and single dose prophylactic intrathecal methotrexate and was maintained on tyrosine kinase therapy and eventually underwent allogenic stem cell transplantation.

1. Introduction

Blast crisis in CML is defined by the presence of \( \geq 20\% \) blasts in the bone marrow or peripheral blood, large clusters of blasts in the bone marrow biopsy; or any extramedullary blast proliferation [1]. Extramedullary disease occurs in a small percent of CML cases and is found to manifest in its chronic, accelerated, or blast phase [2, 3]. It can occur at various sites including bone, lymph node, skin, soft tissue, and central nervous system (CNS) [3–6]. We describe an unusual case of relapsed chronic myelogenous leukemia (CML) in blast crisis presenting with isolated ocular involvement in a patient undergoing imatinib therapy and hematologically in morphologic, cytogenetic, and molecular remission at the time of relapse.

2. Case Presentation

Our patient is a 66-year-old male who was first diagnosed with CML after presenting to the emergency room with acute onset knee pain. During the investigation, he was found to have an elevated white blood cell count (64.4 \( \times \) 10^9/L). The differential count revealed neutrophilia with left shift and basophilia. A subsequent bone marrow biopsy showed morphologic features consistent with chronic phase of CML. Conventional karyotyping and fluorescence in situ hybridization (FISH) on the bone marrow aspirate (Figure 9) showed evidence of \( t(9;22) \) \( BCR-ABL1 \) rearrangement and real time quantitative PCR was positive for \( M-BCR/ABL \) \( t(9;22) \), p210 fusion transcript. The patient was started on imatinib 400 mg once a day. He achieved major molecular...
response after 3 months of therapy and was followed up every 3–4 months thereafter with M-BCR/ABL [t(9;22), p210] fusion gene transcript levels in peripheral blood by real time quantitative PCR.

He remained in remission for three years after initial diagnosis, when he presented with sudden onset pain and loss of vision in the right eye. Magnetic resonance imaging (MRI) scan showed significant intraorbital and optic nerve enhancement. An infratemporal intraconal fat and intraorbital fat biopsy was negative for malignancy. The patient's symptoms improved with conservative management by posterior chamber decompression and steroid therapy but his vision never returned to baseline following this episode. A follow-up MRI 2 months later showed no residual signs of enhancement. Eight months following this episode, he presented with recurrent pain in the right eye, which did not resolve with conservative management. As a result, the patient underwent enucleation of his right eye.

On gross examination, a cross section of the eye showed diffuse circumferential thickening of the choroid (Figure 1). Microscopic examination revealed dense infiltration of the choroid and iris and optic nerve margin by a monotonous mononuclear cell infiltrate morphologically resembling blasts (Figures 2 and 3). By flow cytometry (Figure 4), the blasts were positive for CD34 and demonstrated myeloid immunophenotype expressing CD13, CD33, and CD11c. Blasts were negative for specific lymphoid markers including CD19, CD20, CD79a, CD2, cytoplasmic CD3, CD5, and CD10. However, CD7 was aberrantly coexpressed by the blasts. Interestingly, the blasts did not show cytoplasmic myeloperoxidase (MPO) and terminal deoxynucleotidyl transferase (TdT) expression by flow cytometry. By immunohistochemical staining (Figures 5–7), the blasts were positive for CD34 (Figure 5) with focal expression of variable intensity for CD117 (Figure 6) and strong and diffuse expression of TdT (Figure 7) but were negative for B- or T-lineage lymphoid antigen markers (CD20, CD3, and CD79a) (not shown). FISH cytogenetic analysis on vitreous fluid (Figure 8) demonstrated presence of BCR/ABL [t(9;22)] gene rearrangement identical to the abnormalities detected in the original bone marrow (Figure 9) in which the diagnosis of CML was rendered. In addition to Philadelphia chromosome (Ph), a complex karyotype including trisomy 8 and gain of chromosomes 9 and 22 was also detected in this analysis. In view of the patient’s history, a diagnosis of CML in blast phase was rendered. A subsequent bone marrow exam showed no morphologic, cytogenetic, or molecular evidence of CML or acute leukemia. Cytological evaluation and flow cytometry of cerebrospinal fluid were also negative for disease involvement. The patient underwent induction therapy with idarubicin and cytarabine and a single dose of intrathecal methotrexate. He was maintained on dasatinib 150 mg daily but was switched back to imatinib due to intolerance to dasatinib. He subsequently underwent allogenic stem cell transplantation after 5 months.

3. Discussion

Extramedullary blast crisis in CML is a rare occurrence. In a study of 235 CML patients by Specchia et al. [2], 16% developed extramedullary blast crisis. While both myeloid and lymphoid blast transformations are described, 80% of transformations are of myeloid origin, whereas lymphoblastic transformations account for approximately 20%. Among the latter, B-lymphoblastic transformations are more common than T-lymphoblastic crisis [4, 7]. A recent study looking...
at outcomes found no significant difference in overall survival of CML in myeloid versus lymphoid blast crisis [7]. Ocular manifestations as presenting feature of CML have been previously described. The first case report of ocular involvement by CML in blast phase was published by Alegre et al. [8] but the patient had evidence of disease at other sites. Isolated ocular blast crisis was first described by Lipton et al. [9], who reported a case of relapsed CML presenting as lymphoid blast crisis. In their patient, lymphoid blast crisis was also the initial presentation of the disease at the time of diagnosis. Conversely, our patient initially presented in chronic phase of CML and relapsed with myeloid blast crisis in the eye. Immunophenotypically by flow cytometry, the blasts expressed CD34, CD13, and CD33 with a subset expressing CD117 whereas they were negative for cytoplasmic MPO, TdT, and B- (CD19, CD22, CD79a, and CD10) as well as
T-lymphoid antigen markers (cytoplasmic CD3). In contrast to flow cytometry, the blasts were strongly and uniformly positive for TdT by immunohistochemistry. The reason for this discrepancy is not entirely clear but we speculate that the lack of TdT expression by flow cytometry may be attributed to failure of permeabilization step in the protocol for assessment of cytoplasmic markers. The lack of expression of lymphoid markers and positivity for CD13, CD33, and CD117 was consistent with myeloid immunophenotype for the blasts.

In our case, the patient was treated with cytarabine/doxorubicin and intrathecal methotrexate. Imatinib mesylate is considered first-line therapy for treatment of CML in chronic phase with majority of patients achieving complete cytogenetic and major molecular response. Sudden evolution of disease into blast phase can rarely occur while the patient is on imatinib therapy [10]. Isolated CNS involvement by CML in blast phase has been reported in patients receiving imatinib mesylate treatment [11, 12]. It usually presents as a relapse following an initial complete remission on imatinib or after bone marrow transplant. In some patients, there may be no signs of disease involvement in the blood and bone marrow at time of CNS manifestation [12]. The central nervous system is relatively prone to disease involvement while on imatinib therapy and this is attributed mainly to poor permeability of imatinib through the blood brain barrier [11, 13]. The most common sites of CNS involvement are the lateral ventricular walls [14], meninges [15], and the optic nerve [16], causing symptoms such as headache, cognitive changes, raised intracranial pressure, and visual disturbances. Intraocular optic nerve involvement has been associated with poor prognosis and impermeability to intrathecal chemotherapeutic agents [17]. Increasing reports of CNS involvement by CML in different phases have necessitated broader disease monitoring, including BCR-ABL1 gene quantification in CSF [14]. Second-generation tyrosine kinase
inhibitors (TKI) such as dasatinib are more effective in treating CNS disease [18] due to better penetration of the blood brain barrier [19]. For these reasons, dasatinib and nilotinib are now FDA-approved as first-line therapy in CML [20].

In our patient, the chromosome study was positive for t(9;22)(q34;q11) translocation, FISH showed BCR/ABL fusion gene, and RT-PCR assay was positive for major BCR-ABL mRNA expression. His previously documented diagnosis of chronic phase CML was helpful in diagnosing his ocular blast proliferation/myeloid sarcoma as a blast phase of CML rather than a genetically different de novo acute myeloid leukemia [4, 21, 22]. While blast proliferation in an extramedullary setting would be most consistent with a diagnosis of myeloid sarcoma, since our patient had a documented history of CML, we preferred to use the term blast phase of CML to guide therapeutic decisions. While t(9;22)(q34;q11) translocation is most commonly associated with CML or precursor B-ALL, its presence can be rarely seen in acute myeloid leukemia with a reported incidence of 1-2% of all AML cases. In the absence of a prior chronic or accelerated phase of CML, distinction between blast phase of CML and Philadelphia chromosome-positive (Ph+) AML can be difficult, as they exhibit a major overlap in their clinical presentation and genetic features [23]. Nevertheless, presence of splenomegaly, basophilia, and chromosomal abnormalities in addition to Philadelphia chromosome and a previous history of chronic or accelerated phase CML have all been attributed to blast phase of CML over Ph+ AML [24, 25].

At the time of relapse, in addition to t(9;22)(q34;q11) reciprocal translocation (Ph+), our patient demonstrated other chromosomal aberrations including trisomy 8 and gains of chromosomes 9 and 22. Trisomy 8 has been frequently associated with clonal evolution in CML patients on imatinib who are otherwise in complete cytogenetic remission [26]. At the genetic level, trisomy 8 has been linked to alterations of MYC located at 8q24 [26]. Interestingly, no MYC alterations were detected in our patient. Gains of chromosomes 9 and 22 appear to be nonrandom chromosomal aberrations and perhaps contribute to overall genomic instability; however, the mechanisms of clonal evolution in CML are not well understood.

Using whole genome sequencing, Calabretta and Perrotti [26] found mutations in 9 genes, including GATA2, MAX, ENO1, and ANO5, which were linked to progression of CML to blast phase. Gain-of-function mutations in GATA2 were described in a previous study which reported myeloid blast transformation in CML [27]. MAX gene, through its complex interactions with MYC [28] and CEBPA [29], has been linked to tumor progression [30]. ENO1 acts as a transcriptional repressor of MYC [31]. Recently it has been shown that transcription regulators, including Hes1 and EvI, are involved in disease progression and even confer resistance to tyrosine kinase inhibitors [32, 33]. Many recent studies have identified potential markers as a means of better monitoring of disease progression. SYK gene activation is one such potential marker of disease progression and dasatinib resistance [34, 35].

4. Conclusions

While extramedullary manifestation of CML is rare, a high degree of suspicion is warranted in patients with CML on imatinib therapy who manifest CNS or ocular symptoms, even in the absence of any hematologic, cytogenetic, or molecular evidence of disease. Despite advances in molecular disease detection, more sensitive and effective methods of monitoring disease progression are still needed.

Abbreviations

CML: Chronic myelogenous leukemia
FISH: Fluorescent in situ hybridization
CNS: Central nervous system
PCR: Polymerase chain reaction
MRI: Magnetic resonance imaging
FDA: Food and Drug Administration.

Ethical Approval

The above study was approved by the Institutional Review Board at Henry Ford Hospital, Detroit, Michigan, USA.

Consent

Written informed consent was obtained from the patient for publication of the case report and any accompanying images.

Conflict of Interests

The authors declare that they have no competing interests.

Authors’ Contribution

Rohit Gulati did the data collection, grossing of the surgical specimen in patient care, drafted the paper, and reviewed literature. Yaser Alkhatib helped in data collection from clinical aspects and helped in formulation of the paper. Michelle Madden Felicella conducted the grossing of the specimen supervising Rohit Gulati, helped in paper completion, and took images of the surgical specimen. Vijayalakshmi Donthreddy is the oncologist of the patient and helped collect pertinent points of patient clinical history and completing the paper. Madhu P. Menon played a significant role in paper completion and critically analyzing the review of the literature. Kedar V. Inamdar is the primary hematopathologist for the case and played a significant role in data collection, selecting microscopic images, critically analyzing the data, and reviewing literature and paper preparation.

References

[1] J. W. Vardiman, N. L. Harris, and R. D. Brunning, “The World Health Organization (WHO) classification of the myeloid neoplasms,” Blood, vol. 100, no. 7, pp. 2292–2302, 2002.
[2] G. Specchia, G. Palumbo, D. Pastore, D. Mininini, A. Mestice, and V. Liso, “Extramedullary blast crisis in chronic myeloid
leukemia,” Leukemia Research, vol. 20, no. 11-12, pp. 905–908, 1996.

[3] D. Inverardi, M. Lazzarino, E. Morra et al., “Extramedullary disease in PH+-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance,” Haematologica, vol. 75, no. 2, pp. 146–148, 1990.

[4] G.-N. Jin, P. Zou, W.-X. Chen, Z.-Y. Ding, and H. Zhou, “Fluorescent in situ hybridization diagnosis of extramedullary nodal blast crisis,” Diagnostic Cytopathology, vol. 41, no. 3, pp. 253–256, 2013.

[5] P. J. Van Dijken, M. Niazi, and R. H. Al-Asiri, “Extramedullary blast transformation in a child with adult chronic myelocytic leukemia,” Cancer Genetics and Cytogenetics, vol. 76, no. 2, pp. 151–153, 1994.

[6] S. Tsukamoto, S. Ota, C. Ohwada et al., “Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation,” Leukemia Research Reports, vol. 2, no. 2, pp. 67–69, 2013.

[7] Y.-L. Liu, X. N. Wang, and H. S. Liu, “Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 22, no. 3, pp. 629–633, 2014.

[8] A. Alegre, E. Ojeda, R. Mataix, and T. Molero, “Ocular infiltrates as a presenting form of extramedullary blast crisis in CML,” SMC, vol. 35, no. 3, pp. 236–237, 1990.

[9] J. H. Lipton, H. D. Mcgowan, and D. G. Payne, “Ocular masquerade syndrome in lymphoid blast crisis of chronic myeloid leukemia,” Leukemia and Lymphoma, vol. 20, no. 1-2, pp. 161–163, 1995.

[10] I. Voican, A. M. Vlădăreanu, H. Bumbea, and M. Begu, “Sudden blast crisis in a chronic myeloid leukemia patient during imatinib therapy,” Romanian Journal of Internal Medicine, vol. 50, no. 3, pp. 241–244, 2012.

[11] Y. Isobe, K. Sugimoto, A. Masuda, Y. Hamano, and K. Oshimi, “Central nervous system is a sanctuary site for chronic myelogenous leukemia treated with imatinib mesylate,” Internal Medicine Journal, vol. 39, no. 6, pp. 408–411, 2009.

[12] S. Bujassoum, J. Rifkind, and J. H. Lipton, “Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy,” Leukemia and Lymphoma, vol. 45, no. 2, pp. 401–403, 2004.

[13] J. E. Leis, D. E. Stepan, P. T. Curtin et al., “Central nervous system failure in patients with chronic myelogenous leukemia blast phase and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571),” Leukemia and Lymphoma, vol. 45, no. 4, pp. 695–698, 2004.

[14] M. Fuchs, M. Reinhofer, A. Ragoschke-Schumm et al., “Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation,” BMC Blood Disorders, vol. 12, article 9, 2012.

[15] T. K. Saikia, B. Dhabhar, R. S. Iyer et al., “High incidence of meningeal leukemia in lymphoid blast crisis of chronic myelogenous leukemia,” American Journal of Hematology, vol. 43, no. 1, pp. 10–13, 1993.

[16] A. Thomas, C. K. Stein, T. C. Gentile, and C. M. Shah, “Isolated CNS relapse of CML after bone marrow transplantation,” Leukemia Research, vol. 34, no. 4, pp. e113–e114, 2010.

[17] T. Sharma, J. Grewal, S. Gupta, and P. I. Murray, “Ophthalmic manifestations of acute leukemias: the ophthalmologist’s role,” Eye, vol. 18, no. 7, pp. 663–672, 2004.

[18] M. J. Taylor and P. A. Schuffham, “Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 9, no. 2, pp. 117–121, 2009.

[19] K. Porkka, P. Koskenvesa, T. Lundan et al., “Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia,” Blood, vol. 112, no. 4, pp. 1005–1012, 2008.

[20] C. Fava, G. Rege-Cambrin, and G. Saglio, “The choice of first-line chronic myelogenous leukemia treatment,” Annals of Hematology, vol. 94, supplement 2, pp. S123–S131, 2015.

[21] S. H. Sverdlow, E. Campo, N. Harris et al., Eds., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, France, 2008.

[22] J. Wei, M. Huang, Y. Wang, and J. Zhou, “Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-Cell lymphoblastic lymphoma,” Onkologie, vol. 36, no. 3, pp. 119–122, 2013.

[23] C. P. Soupir, J.-A. Vergilio, P. Dal Cin et al., “Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis,” American Journal of Clinical Pathology, vol. 127, no. 4, pp. 642–650, 2007.

[24] R. Berger, “Differences between blastic chronic myeloid leukemia and ph-positive acute leukemia,” Leukemia and Lymphoma, vol. 11, supplement 1, pp. 235–237, 1993.

[25] A. Cuneo, A. Ferrant, J.-L. Michaux et al., “Philadelphia chromosome-positive acute myeloid leukemia: cytokinemonologic and cytogenetic features,” Haematologica, vol. 81, no. 5, pp. 423–427, 1996.

[26] B. Calabretta and D. Perrotti, “The biology of CML blast crisis,” Blood, vol. 103, no. 11, pp. 4010–4022, 2004.

[27] S.-J. Zhang, L.-Y. Ma, Q.-H. Huang et al., “Gain-of-function mutation of GATA-2 in acute myeloid leukemia with clinicopathologic features distinct from chronic myeloid leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 2076–2081, 2008.

[28] C. V. Dang, “MYC on the path to cancer,” Cell, vol. 149, no. 1, pp. 22–35, 2012.

[29] A. A. Zada, J. A. Pulikkan, D. Bararia et al., “Proteomic discovery of Mix2 as a novel interacting partner of C/EBPα: a Myc/Mix/Mad link,” Leukemia, vol. 20, no. 12, pp. 2137–2146, 2006.

[30] Y. Huang, J. Zheng, J. D. Hu et al., “Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing,” Genetics and Molecular Research, vol. 13, no. 1, pp. 945–953, 2014.

[31] S. Feo, D. Arcuri, E. Piddini, R. Passantino, and A. Giallongo, “ENOL gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1),” FEBS Letters, vol. 473, no. 1, pp. 47–52, 2000.

[32] T. Sato, “Evil defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia,” Oncogene, vol. 33, no. 42, pp. 5028–5038, 2014.

[33] F. Nakahara, J. Kitaura, T. Uchida et al., “Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells,” Blood, vol. 123, no. 25, pp. 3932–3942, 2014.
[34] C. Bourgne, A. Janel, J. Berger et al., “Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk\textsuperscript{348}) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML),” *Leukemia Research*, vol. 39, no. 3, pp. 329–334, 2015.

[35] F. El Rassi, J. D. Bergsagel, M. Arellano et al., “Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?” *Cancer*, vol. 121, no. 6, pp. 872–875, 2015.
